Genetic variants that reduce the editing levels of double-stranded RNA are associated with autoimmune and immune-mediated conditions, a study finds.

Results from a small sample of Indian males suggest that lean individuals with a history of malnutrition suffer from a distinct type of diabetes characterized by a defect in insulin secretion.

Researchers have collected hundreds of COVID-19–related diabetes case reports since August of last year, in hopes of teasing apart the complex links between the two diseases.

The University of Texas Southwestern scientist studied the roles of glucagon and insulin in regulating blood glucose, leading to several successful treatments.

Insulin-producing cells grown in the lab could offer a functional cure for the disease.

A rogue hybrid lymphocyte, bearing characteristics of both B and T cells, may play a role in driving autoimmunity in the disease, although the mechanism is far from clear.

When implanted into mice, the “pseudo-islets” helped treat the animals’ diabetes symptoms.

Researchers find that it’s not just high-risk genes, but how children’s bodies respond to their own intestinal microbiota that relates to future diagnoses of type 1 diabetes.

Results from an observational study find that the introduction of a routine vaccine in Australia coincided with a fall in the incidence of the autoimmune condition.

The original work found that an anti-malaria drug or the neurotransmitter GABA could increase the number of insulin-producing pancreatic cells in mice.

Researchers used a trio of transcription factors to transform pancreatic duct cells in vivo into β-like cells that secrete insulin and improve diabetes symptoms.

The new classification system could help improve personalized medicine approaches to the disease.

Pancreatic cells engineered to produce insulin did not immediately provoke an immune response.

Scientists build a biosensor skin patch for noninvasive glucose monitoring. 

A needle-free alternative to the finger-prick test would be a godsend for many sufferers of diabetes, but the industry has yet to clear the technological hurdles.

A small clinical trial demonstrates that peptide immunotherapy can halt the progression of early-stage type 1 diabetes.

The diabetic volunteer continued to produce insulin one year after she received a transplant of abdominal islet cells.

Three therapeutic doses administered during early life disturb the animals’ microbiomes and lead to enduring changes in the immune systems of non-obese diabetic mice, researchers report.